
Michael J. Keating, M.B., B.S.
Department of Leukemia, Division of Cancer Medicine
About Dr. Keating
Over the last 30 years, he has been involved in clinical research in chronic lymphocytic leukemia (CLL). During this time the complete remission rate has risen dramatically from approximately 5% to 50 – 60%. This is associated with... improvements in developmental therapeutic programs but also a dramatic improvement in the understanding of the biology and prognostic factors of CLL. CLL is a disease of the elderly and the characterization of other cancers in survivors of CLL is vitally important. Understanding of this comparison between incidence and characteristics of other cancers in CLL survivors is vitally important in its own right but must be integrated into clinical understanding of the disease. He is totally committed to providing clinical and intellectual resources at his disposal to support the program.
In the News
Present Title & Affiliation
Primary Appointment
Clinical Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Clinical Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
1966 | University of Melbourne, Melbourne, AU, Medicine, MBBS |
1966 | St. Vincent's Hospital, Clinical School, Fitzroy, AU, Medicine, MBBS |
Postgraduate Training
1974-1975 | Fellow, The University of Texas System Cancer Center, Houston, Texas |
1971-1973 | Third Assistant, University of Melbourne, Melbourne |
1970-1971 | Senior Registrar, University of Melbourne, Melbourne |
1970-1970 | Fellow, Royal Australasian College of Physicians, Sydney |
1969-1970 | Medical Registrar, St. Vincent's Hospital, Melbourne |
1967-1968 | Residency in Medicine Surgery, St. Vincent's Hospital, Fitzroy |
Board Certifications
1970 | Royal Australasian College of Physicians |
Experience & Service
Academic Appointments
Professor of Medicine and Internist, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 1999 - 2014
Associate Head for Clinical Research, Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 1995 - 1999
Associate VP for Clinical Investigations, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 1990 - 1995
Professor of Medicine and Internist, Department of Hematology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 1984 - 1990
Associate Professor of Medicine and Internist, Department of Hematology, The University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Houston, TX, 1983 - 1984
Associate Professor of Medicine and Associate Internist, Department of Developmental Therapeutics, The University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Houston, TX, 1980 - 1983
Assistant Professor of Medicine and Assistant Internist, Department of Developmental Therapeutics, The University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Houston, TX, 1978 - 1980
Senior Lecturer, Department of Medicine, St. Vincent's Hospital, Melbourne, 1977 - 1978
Faculty Associate, Department of Developmental Therapeutics, The University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Houston, TX, 1975 - 1976
Administrative Appointments/Responsibilities
Chief, Section of Chronic Leukemias, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 1999 - Present
Chief, Section of Clinical Studies, Department of Hematology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1984 - 1989
Other Appointments/Responsibilities
Member, Program Committee, American Society of Clinical Oncology, Houston, TX, 1987
Institutional Committee Activities
Member, Conflict of Interest Committee, 2005 - 2010
Member, Retirement Board Committee, 1997 - 2010
Chairman, Institutional Research Grant Committee, 1986 - 1987
Member, Information Systems Advisory Group Committee, 1984 - 1988
Member, Surveillance Committee, 1982 - 1986
Co-Chair, Medical Records Committee, 1982 - 1986
Member, Investigational Drug Committee, 1982 - 1986
Chairman, Pharmacy and Therapeutics Committee, 1981 - 1994
Honors & Awards
2014 | Provost's Distinguished Clinical Faculty Mentor, University of Texas MD Anderson Cancer Center |
2009 | Dr. Jenaro Haddock Award, Puerto Rico Society of Hematology |
2008 | Rofeh Yedid Award, Aishel House |
2008 | State of Israel Maimonides Award, State of Israel Bonds |
2007 | Gerald P. Bodey, Sr. Distinguished Professorship Award, M. D. Anderson Cancer Center |
2002 | Charles A. LeMaistre, M. D. Outstanding Achievement Award in Cancer, M. D. Anderson Cancer Center |
2002 | Rai and Binet Medal, International Workshop on CLL |
2001 | Dr. John J. Kenny Award, Leukemia and Lymphoma Society |
1996 | Best Doctor in America (Leukemia), American Health Magazine |
1993 - 2014 | Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research, M. D. Anderson Cancer Center |
1993 | Faculty Achievement Award in Clinical Research, M. D. Anderson Cancer Center |
1989 | Carl de Gruchy Award Visiting Professorship, Hematology Society of Australia |
1988 | Service to Mankind Award, Leukemia Society of America, Texas Gulf Coast Chapter |
1982 - 1987 | Scholar, Leukemia Society of America |
Selected Publications
Peer-Reviewed Articles
- Veletic I, Harris DM, Rozovski U, Bertilaccio MTS, Calin GA, Takahashi K, Li P, Liu Z, Manshouri T, Drula RC, Furudate K, Muftuoglu M, Hossain A, Wierda WG, Keating MJ, Estrov Z. CLL cell-derived exosomes alter the immune and hematopoietic systems. Leukemia 39(6):1380-1394, 2025. e-Pub 2025. PMID: 40186065.
- Chen LS, Bose P, Qiao W, Jiang Y, Wu Q, Cruz ND, Keating MJ, Gandhi V. A pilot study of lower doses of ibrutinib: patient body weight does not correlate with plasma ibrutinib levels during therapy. Leuk Lymphoma 66(6):1166-1168, 2025. e-Pub 2025. PMID: 39921535.
- Bayraktar R, Tang Y, Dragomir MP, Ivan C, Peng X, Fabris L, Zhang J, Carugo A, Aneli S, Liu J, Chen MM, Srinivasan S, Sahnoune I, Bayraktar E, Akdemir KC, Chen M, Narayanan P, Huang W, Ott LF, Eterovic AK, Villarreal OE, Mohammad MM, Peoples MD, Walsh DM, Hernandez JA, Morgan MB, Shaw KR, Davis JS, Menter D, Tam CS, Yeh P, Dawson SJ, Rassenti LZ, Kipps TJ, Kunej T, Estrov Z, Joosse SA, Pagani L, Alix-Panabieres C, Pantel K, Ferajoli A, Futreal A, Wistuba II, Radovich M, Kopetz S, Keating MJ, Draetta GF, Mattick JS, Liang H, Calin GA. The mutational landscape and functional effects of noncoding ultraconserved elements in human cancers. Sci Adv 11(8):eado2830, 2025. e-Pub 2025. PMID: 39970212.
- Zhang R, Khare P, Banerjee P, Ivan C, Schneider S, Barbaglio F, Clise-Dwyer K, Jensen VB, Thompson E, Mendoza M, Chiorazzi N, Chen SS, Yan XJ, Jain N, Ghia P, Caligaris-Cappio F, Mendonsa R, Kasimsetty S, Swoboda R, Bayraktar R, Wierda W, Gandhi V, Calin GA, Keating MJ, Bertilaccio MTS. The DLEU2/miR-15a/miR-16-1 cluster shapes the immune microenvironment of chronic lymphocytic leukemia. Blood Cancer J 14(1):168, 2024. e-Pub 2024. PMID: 39438453.
- Liu P, Wang K, Li J, Ogasawara MA, Xia Z, Wierda WG, Keating MJ, Li Y, Huang P. Global miRNA profiling reveals key molecules that contribute to different chronic lymphocytic leukemia incidences in Asian and Western populations. Haematologica 109(2):479-492, 2024. e-Pub 2024. PMID: 37646669.
- Thompson PA, Bazinet A, Wierda WG, Tam CS, O'Brien SM, Saha S, Peterson CB, Plunkett W, Keating MJ. Sustained remissions in CLL after frontline FCR treatment with very long-term follow-up. Blood 142(21):1784-1788, 2023. e-Pub 2023. PMID: 37595283.
- Corvigno S, Badal S, Spradlin ML, Keating M, Pereira I, Stur E, Bayraktar E, Foster KI, Bateman NW, Barakat W, Darcy KM, Conrads TP, Maxwell GL, Lorenzi PL, Lutgendorf SK, Wen Y, Zhao L, Thaker PH, Goodheart MJ, Liu J, Fleming N, Lee S, Eberlin LS, Sood AK. In situ profiling reveals metabolic alterations in the tumor microenvironment of ovarian cancer after chemotherapy. NPJ Precis Oncol 7(1):115, 2023. e-Pub 2023. PMID: 37923835.
- Gordon MJ, Jones JE, George B, Peterson C, Burger JA, Jain N, Keating M, Wierda WG, Durand JB, Ferrajoli A. Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity. Cancer 129(14):2192-2200, 2023. e-Pub 2023. PMID: 37016930.
- Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv 7(10):1958-1966, 2023. e-Pub 2023. PMID: 36287248.
- Thompson PA, Keating MJ, Ferrajoli A, Jain N, Peterson CB, Garg N, Wang SA, Jorgensen JL, Kadia TM, Bose P, Pemmaraju N, Short NJ, Wierda WG. Venetoclax consolidation in high-risk CLL treated with ibrutinib for =1 year achieves a high rate of undetectable MRD. Leukemia. e-Pub 2023. PMID: 37138019.
- Boddu PC, Senapati J, Ravandi-Kashani F, Jabbour EJ, Jain N, Ayres M, Chen Y, Keating MJ, Kantarjian HM, Gandhi V, Kadia TM. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies. Cancer 129(4):580-589, 2023. e-Pub 2023. PMID: 36448227.
- Rozovski U, Veletik I, Harris D, Li P, Liu Z, Jain P, Manshouri T, Ferrajoli A, Burger J, Bose P, Thompson P, Jain N, Wierda W, Verstovsek S, Keating M, Estrov Z. CLL-162 PTX3 is Constitutively Active in CLL Cells. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S271, 2022. e-Pub 2022. PMID: 36163878.
- Thompson PA, Jiang X, Banerjee P, Basar R, Garg N, Chen K, Kaplan M, Nandivada V, Cortes AKN, Ferrajoli A, Keating MJ, Peterson CB, Andreeff M, Rezvani K, Wierda WG. A phase two study of high dose blinatumomab in Richter's syndrome. Leukemia 36(9):2228-2232, 2022. e-Pub 2022. PMID: 35941212.
- Cherng HJ, Khwaja R, Kanagal-Shamanna R, Tang G, Burger J, Thompson P, Ferrajoli A, Estrov Z, Sasaki K, Sampath D, Wang X, Kantarjian H, Keating M, Wierda WG, Jain N. TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis. Am J Hematol 97(8):1005-1012, 2022. e-Pub 2022. PMID: 35567779.
- Tettamanti S, Rotiroti MC, Giordano Attianese GMP, Arcangeli S, Zhang R, Banerjee P, Galletti G, McManus S, Mazza M, Nicolini F, Martinelli G, Ivan C, Veliz Rodriguez T, Barbaglio F, Scarfò L, Ponzoni M, Wierda W, Gandhi V, Keating M, Biondi A, Caligaris-Cappio F, Biagi E, Ghia P, Bertilaccio MTS. Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia. Leuk Lymphoma 63(7):1-14, 2022. e-Pub 2022. PMID: 35259043.
- Rozovski U, Veletic I, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Verstovsek S, Keating MJ, Estrov Z. STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells. J Immunol 208(12):2847-2855, 2022. e-Pub 2022. PMID: 35595309.
- Chen R, Chen Y, Xiong P, Zheleva D, Blake D, Keating MJ, Wierda WG, Plunkett W. Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells. Leukemia 36(6):1596-1608, 2022. e-Pub 2022. PMID: 35383271.
- Sivina M, Kim E, Wierda WG, Ferrajoli A, Jain N, Thompson P, Kantarjian H, Keating M, Burger JA. Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion/TP53 mutations. Blood 138(24):2589-2592, 2021. e-Pub 2021. PMID: 34521099.
- Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia 35(12):3421-3429, 2021. e-Pub 2021. PMID: 34007049.
- Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol 7(8):1213-1219, 2021. e-Pub 2021. PMID: 34110383.
- Cherng HJ, Jammal N, Paul S, Wang X, Sasaki K, Thompson P, Burger J, Ferrajoli A, Estrov Z, O'Brien S, Keating M, Wierda WG, Jain N. Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. Br J Haematol 194(1):61-68, 2021. e-Pub 2021. PMID: 33973230.
- Sivina M, Xiao L, Kim E, Vaca A, Chen SS, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Huang X, Chiorazzi N, Burger JA. CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia. Leukemia 35(6):1610-1620, 2021. e-Pub 2021. PMID: 33087831.
- Assi R, Kantarjian H, Keating M, Pemmaraju N, Verstovsek S, Garcia-Manero G, Ravandi F, Borthakur G, Dahl J, Jabbour E, Cortes JE. Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience. Leuk Lymphoma 62(4):1-14, 2021. e-Pub 2021. PMID: 33283580.
- Chen R, Tsai J, Thompson PA, Chen Y, Xiong P, Liu C, Burrows F, Sivina M, Burger JA, Keating MJ, Wierda WG, Plunkett W. The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action. Blood Cancer J 11(3):57, 2021. e-Pub 2021. PMID: 33714981.
- Rozovski U, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Veletic I, Ferrajoli A, Bose P, Thompson P, Jain N, Verstovsek S, Wierda W, Keating MJ, Estrov Z. STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. Oncotarget 12(5):401-411, 2021. e-Pub 2021. PMID: 33747356.
- Yi X, Sarkar A, Kismali G, Aslan B, Ayres M, Iles LR, Keating MJ, Wierda WG, Long JP, Bertilaccio MTS, Gandhi V. AMG-176, an Mcl-1 antagonist, shows preclinical efficacy in chronic lymphocytic leukemia. Clin Cancer Res 26(14):3856-3867, 2020. e-Pub 2020. PMID: 31937611.
- Kim E, Ten Hacken E, Sivina M, Clarke A, Thompson PA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG, Bhalla KN, Burger JA. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia 34(6):1588-1598, 2020. e-Pub 2020. PMID: 31862959.
- Strati P, Schlette EJ, Solis Soto LM, Duenas DE, Sivina M, Kim E, Keating MJ, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Wistuba II, Burger JA. Achieving Complete Remission in CLL Patients Treated with Ibrutinib: Clinical Significance and Predictive Factors. Blood 135(7):510-513, 2020. e-Pub 2020. PMID: 31895947.
- Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med 382(6):545-553, 2020. e-Pub 2020. PMID: 32023374.
Manuals, Teaching Aids, Other Teaching Publications
- Rozovski U, Hazan-Halevy I, Calin G, Harris D, Li P, Liu Z, Keating MJ, Estrov Z. Describing a transcription factor dependent regulation of the MicroRNA transcriptome. Journal of Visualized Experiments (JoVE), 2016.
Abstracts
- Abuasab T, Haddad F, Mohamed SF, Jorgensen JL, Wang SA, Thompson PA, Kadia TM, Alvarado Y, Pierce SA, Keating MJ, McCue D, Kantarjian H, Ravandi F. Utility of Flow Cytometry in Monitoring of Measurable Residual Disease in Patients with Hairy Cell Leukemia. Blood 140(Suppl. 1):9365-9386, 2022. e-Pub 2022.
- Cherng HJ, Jammal N, Paul S, Wang X, Sasaki K, Thompson PA, Burger JA, Ferrajoli A, Estrov ZE, O'Brien SM, Keating MJ, Wierda WG, Jain N. Examination of Clinical and Molecular Characteristics and Treatment Patterns of Adolescent and Young Adult (AYA) Patients with Chronic Lymphocytic Leukemia. Blood 136(Supp 1):5-6, 2020. e-Pub 2020.
- Jones J, George BS, Peterson CB, Ha TT, Burger JA, Jain N, Keating MJ, Wierda WG, Durand J, Ferrajoli A. Hypertension, Cardiovascular and Renal Complications Observed in Patients with Chronic Lymphocytic Leukemia Receiving Long-Term Therapy with Ibrutinib. Blood 136(Supp 1):27-28, 2020. e-Pub 2020.
- Thompson PA, Ferrajoli A, Jain N, Wang Y, Peterson CB, Garg N, Wei C, Ayala A, Kadia TM, Bose P, Pemmaraju N, Short NJ, Keating MJ, Wierda WG. The Addition of Venetoclax to Ibrutinib Achieves a High Rate of Undetectable Minimal Residual Disease in Patients with High-Risk CLL. Blood 136(Supp 1):28-29, 2020. e-Pub 2020.
- Sivina M, Jain N, Kim E, Kadia TM, Estrov ZE, Ohanian M, Andreeff M, Thomas M, Thompson PA, Kantarjian HM, Keating MJ, O'Brien SM, Wierda WG, Ferrajoli A, Burger JA. Ibrutinib Induces Durable Remissions in Treatment-Naïve CLL Patients with 17p Deletion/TP53 Mutations: Five Year Follow-up from a Phase 2 Study. Blood 136(Supp 1):22-23, 2020. e-Pub 2020.
- Jain N, MJ <, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov ZE, Sasaki K, Fowler NH, Kadia TM, Konopleva M, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen JL, Wang, SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results. Blood 136(Supp 1):42-43, 2020. e-Pub 2020.
Selected Presentations & Talks
Local Presentations
- 2004. Hematologic Malignancies. Conference. Oncology Education Continuum: A Continuing Medical Education Initiative. Houston, TX, US.
- 2002. Monoclonal Antibody Therapy in Hematological Malignancies. Conference. Oncology Education Continuum. Houston, TX, US.
Regional Presentations
- 2004. Emerging Data and Clinical Trials in Chronic Lymphocytic Leukemia. Conference. Rituxan Community Advisory Board. San Antonio, TX, US.
- 2001. Hematologic Malignancies. Conference. IDEC Pharm. Dallas, TX, US.
- 2001. CLL. Conference. Ilex Oncology. San Antonio, TX, US.
- 2001. Clinical Advances in Leukemia & Lymphomas. Conference. Bayshore Medical Hospital. Pasadena, TX, US.
- 2000. Management of B-Cell Malignancies. Conference. Presbyterian Texas Health Research Institute. Dallas, TX, US.
- 2000. Rising CMV Rates in Leukemia Patients. Conference. Medimmune. Galveston, TX, US.
National Presentations
- 2004. CLL. Conference. ASH. San Diego, CA, US.
- 2004. CLL. Invited. Great Debates in Hematology Annual Meeting. Napa, CA, US.
- 2004. Clinical Research Consortium (CRC) Audit. Conference. Clinical Research Consortium (CRC) Audit. Cleveland, OH, US.
- 2004. Clinical Research Consortium (CRC) Audit. Conference. Clinical Research Consortium (CRC) Audit. Boston, MA, US.
- 2004. CLL. Conference. Clinical Research Consortium (CRC) Grant Renewal Meeting. San Diego, CA, US.
- 2004. CLL. Conference. Clinical Research Consortium (CRC) Annual Meeting. Bethesda, MD, US.
- 2004. CLL. Conference. AACR. Orlando, FL, US.
- 2004. CLL. Invited. ASH Highlights Meeting. San Francisco, CA, US.
- 2004. FCR in Chronic Lymphocytic Leukemia. Invited. Kaiser Permanente Hematology/Oncology Symposium. Los Angeles, CA, US.
- 2003. CLL. Conference. ASH. San Diego, CA, US.
- 2003. CLL. Invited. Evaluating Monoclonal Antibody Therapy for BCE Malignancies. San Francisco, CA, US.
- 2003. CLL. Invited. Evaluating Monoclonal Antibody Therapy for B-Cell Malignancies. San Diego, CA, US.
- 2003. CLL. Conference. PACT (Partnership for Advancing CLL Treatment) Experts Opinion Roundtable. Yountville, CA, US.
- 2003. CLL. Invited. Challenging Cases in Hematology. Las Vegas, NV, US.
- 2003. Current Advances in the Treatment of Lymphatic Malignancies (NHL and CLL). Conference. Videoconference - Webcast. Denver, CO, US.
- 2003. Molecular Oncology for the Practitioner. Invited. Oncological Conference. Neptune, NJ, US.
- 2003. CLL. Invited. ASH Update. Beverly Hills, CA, US.
- 2003. Hematologic Malignancies. Invited. Expanding Options in the Treatment of Non-Hodgkin’s Lymphoma. Nashville, TN, US.
- 2003. New Paradigms for Management of CLL. Invited. Health Science Center for Continuing Medical Education. Pittsburgh, PA, US.
- 2003. CLL. Invited. ASH Highlights. San Diego, CA, US.
- 2003. CLL. Invited. ASH Highlights. New York, NY, US.
- 2002. CLL. Invited. Emerging Issues in the Treatment of B-Cell Lymphoproliferative Disorders. Santa Ana, CA, US.
- 2002. CLL. Conference. ASH. Philadelphia, PA, US.
- 2002. What’s New in Hematology. Conference. Videoconference. Atlanta, GA, US.
- 2001. CLL. Conference. ASH. Orlando, FL, US.
- 2001. CLL. Invited. Challenging Cases in Hematology. New York, NY, US.
- 2001. CLL. Invited. Clinical Advances in Leukemia & Lymphomas. Little Rock, AR, US.
- 2001. Clinical Trials – Prioritization of Clinical Trials. Invited. CRC Annual Meeting. San Diego, CA, US.
- 2001. CLL. Invited. Challenging Cases in Hematology. Miami, FL, US.
- 2001. Campath. Conference. Campath Launch. Phoenix, AZ, US.
- 2001. Circulating CD 20 in CLL Patients. Invited. NWU Medical School 3rd Annual Oncology Option Leader Roundtable. Kailua Kona, HI, US.
- 2001. CLL. Conference. CLL Advisory Board. New York, NY, US.
- 2001. Scholar Clinical Grant Review. Conference. 2001 Scholar Clinical Grant Review Sub Committee Meeting. New York, NY, US.
- 2000. Overview of CLL: Need for New Therapeutic Options. Invited. Oncologic Drug Advisory Communications Conference. Bethesda, MD, US.
- 2000. CLL. Invited. Challenging Cases in Hematology. St. Louis, MO, US.
- 2000. CLL. Invited. Challenging Cases in Hematology. Las Vegas, NV, US.
- 2000. Defining Optimal Treatment Strategies in Hematological Malignancies. Conference. ASH. San Francisco, CA, US.
- 2000. CLL / Campath. Conference. Mock ODAC Session for Campath. Newark, NJ, US.
- 2000. 3-Cell Lymphocyte Stimulator (BlyS) Conjugate. Conference. Human Genome Science Expert Meeting and the 3-Cell Lymphocyte Stimulator (BlyS) Conjugate Experts Meeting. Rockville, MD, US.
International Presentations
- 2004. CLL. Conference. TeGenero Clinical Development Meeting. Frankfurt, DE.
- 2004. CLL. Invited. Challenging Cases in Hematology Meeting. Montreal, CA.
- 2004. CLL. Conference. European Hematology Association (EHA) Meeting. Geneva, CH.
- 2004. CLL. Conference. ASCO. New Orleans, US.
- 2003. CLL. Conference. International Workshop on CLL Meeting. Stresa, IT.
- 2003. CLL. Conference. ASCO. Chicago, US.
- 2003. CLL. Invited. New Insights in Hematology. Venice, IT.
- 2003. Hematologic Malignancies. Conference. 5th Meeting - New Insights in Hematology. Venice, IT.
- 2003. CLL. Invited. International Oncology Symposium. Jupiter Beach, US.
- 2003. CLL. Conference. International Oncology Symposium. Madrid, ES.
- 2003. Hematologic Malignancies. Invited. International Workshop on Lymphoma. Palm Beach, US.
- 2003. Hematologic Malignancies. Conference. International Workshop on Lymphoid Malignancies. Palm Beach, US.
- 2002. CLL. Conference. Pan European Hematology Symposium. Berlin, DE.
- 2001. Campath. Conference. Campath Training. London, GB.
- 2001. CLL. Invited. Challenging Cases in Hematology. Amsterdam, NL.
Formal Peers
- 2014. CLL Data Monitoring Committee Data Update. Invited. Short Hills, NJ, US.
- 2014. CLL. Invited. Indianapolis, IN, US.
- 2014. CLL. Invited. Knoxville, TN, US.
- 2013. CLL. Invited. Knoxville, TN, US.
- 2012. The New Era of CLL. Invited. Chicago, IL, US.
- 2012. How to increase the cure rate of CLL. Invited. Scottsdale, AZ, US.
- 2012. CLL. Invited. Indianapolis, IN, US.
- 2012. CLL. Invited. Knoxville, TN, US.
- 2011. Impersonalized Treatment of Cancer: Vegetables for humans and dogs. Invited. Denver, CO, US.
- 2011. CLL. Invited. Knoxville, TN, US.
- 2010. CLL. Invited. Puebla, MX.
- 2010. CLL. Invited. Chicago, IL, US.
- 2010. Advances in Frontline and Salvage Therapy of CLL. Invited. San Diego, CA, US.
- 2010. Update on Chronic Lymphocytic Leukemia. Invited. Knoxville, TN, US.
- 2009. Challenging Therapeutic Goals in CLL. Invited. Oklahoma City, OK, US.
- 2009. CLL. Invited. Chicago, IL, US.
- 2009. CLL. Invited. Boston, MA, US.
- 2009. ODAC Meeting for Ofatumumab. Invited. Philadelphia, PA, US.
- 2009. CLL. Invited. Indianapolis, IN, US.
- 2008. CLL - Current and Future Therapies. Invited. Asheville, NC, US.
- 2008. Ofatumumab Clinical Program Submission to FDA. Invited. Silver Spring, MD, US.
- 2008. CLL - Chasing the Cure. Invited. Philadelphia, PA, US.
- 2008. Leukemias, Myelodysplasia and Transplantation. Invited. San Francisco, CA, US.
- 2008. Update on Treatment of Lymphoma/Leukemia. Invited. Denver, CO, US.
- 2008. Illuminating Possibilities: Making Strides in the Treatment of B-CLL. Invited. Virginia Beach, VA, US.
- 2008. CLL - A Disease in Transition. Invited. Spartanburg, SC, US.
- 2008. Expanding Horizons: Advances in Targeted Therapies for CLL. Invited. New York, NY, US.
- 2008. Expanding Horizons - Treatment for CLL. Invited. New York, NY, US.
- 2008. CLL. Invited. Las Vegas, NV, US.
- 2008. Illuminating Possibilities: Making Strides in the Treatment of B-CLL. Invited. Vienna, VA, US.
- 2008. CLL. Invited. Miami, FL, US.
- 2008. Update on CLL. Invited. Knoxville, TN, US.
- 2008. CLL Abstracts. Invited. New York, NY, US.
- 2006. CLL. Invited. Rochester, MN, US.
- 2004. CLL. Invited. Los Angeles, CA, US.
- 2004. Clinical Hematology & Oncology 2004. Invited. San Diego, CA, US.
- 2001. Monoclonal Antibodies – Rational Use in CLL. Invited. New York, NY, US.
- 2001. Current Advances in the Treatment of CLL. Invited. Atlanta, GA, US.
- 2001. MabThera in CLL, MabThera Present and Future - Time to Re-assess. Invited. Montreux, CH.
- 2001. Therapy of Relapsed/Refractory CLL. Invited. Mannheim, DE.
- 2001. Chronic Leukemia: Rapidly Changing Field. Invited. Boston, MA, US.
- 2001. Current Status of Alemtuzumab (Campath) in CLL. Invited. Banff Springs, CA.
- 2001. CLL & Other Lymphoma. Invited. São Paulo, BR.
- 2001. Therapy of Low Grade NHL. Invited, CZ.
- 2001. Chronic Lymphocytic Leukemia. Invited. Baton Rouge, LA, US.
- 2001. Clinical Advances in Leukemia & Lymphomas. Invited. Shreveport, LA, US.
- 2001. Clinical Advances in Leukemia & Lymphomas. Invited. Berkeley, CA, US.
- 2001. Clinical Advances in Leukemia & Lymphomas. Invited. Minneapolis, MN, US.
- 2001. Clinical Advances in Leukemia & Lymphomas. Invited. Washington, DC, US.
- 2001. Current Therapeutic Options in the Management of B-Cell Malignancies. Invited. Oklahoma City, OK, US.
- 2001. Current Therapeutic Options in the Management of B-Cell Malignancies. Invited. Atlanta, GA, US.
- 2001. Clinical Advances in Leukemia & Lymphomas. Invited. Springfield, IL, US.
- 2001. Current Advances in Leukemia & Lymphomas. Invited. New Orleans, LA, US.
- 2001. Current Therapeutic Options in the Management of B-Cell Malignancies. Invited. Worchester, MA, US.
- 2001. Current Therapeutic Options in the Management of B-Cell Malignancies. Invited. Honolulu, HI, US.
- 2001. Toxicity / Side Effects / Immunosuppression of Campath – 1H Therapy. Invited. Anaheim, CA, US.
- 2000. Current Therapeutic Options in the Management of B-Cell Malignancies. Invited. Sylvania, OH, US.
- 2000. Current Therapeutic Options in the Management of B-Cell Malignancies. Invited. San Diego, CA, US.
- 2000. Current Therapeutic Options in the Management of B-Cell Malignancies. Invited. Mt. Sinai, NY, US.
- 2000. Current Therapeutic Options in the Management of B-Cell Malignancies. Invited. Memphis, TN, US.
- 2000. Chronic Lymphocytic Leukemia. Invited. Washington, DC, US.
- 2000. Clinical Advances in Leukemias and Lymphomas. Invited. Coral Gables, FL, US.
- 2000. A Changing Paradigm of CLL Treatment. Invited. Indianapolis, IN, US.
- 2000. Current Therapeutic Options in the Management of B-cell Malignancies. Invited. Tupelo, MS, US.
- 2000. Use of Hematopoietic Growth Factors in CLL & Rituximab – The M.D. Anderson Experiences. Invited. Koloster Irsee, DE.
- 2000. Chronic Lymphocytic Leukemia. Invited. Longboat, FL, US.
- 2000. Chronic Lymphocytic Leukemia. Invited. Atlanta, GA, US.
- 2000. A New Paradigm for Treating CLL. Invited. Great Neck, NY, US.
Grant & Contract Support
Date: | 2015 - 2020 |
Title: | Mechanism-based combination of ibrutinib for curing chronic lymphocytic leukemia |
Funding Source: | NIH/NCI |
Role: | Co-I |
ID: | 1R01CA194786-01 |
Title: | Optimizing Therapy of Chronic Lymphocytic Leukemia with Ibrutinib |
Funding Source: | Leukemia and Lymphoma Society |
Role: | Co-I |
CV information above last modified June 10, 2025